Active Ingredient: Ondansetron
For this indication, competent medicine agencies globally authorize below treatments:
For:
Intravenous, 5 milligrams ondansetron per square meter of body surface, once daily, one dose.
The dose for CINV can be calculated based on body surface area (BSA) or weight – see below.
In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 mL of saline or other compatible infusion fluid and infused over not less than 15 minutes.
Weight-based dosing results in higher total daily doses compared to BSA-based dosing.
Ondansetron injection should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid and infused intravenously over not less than 15 minutes.
There are no data from controlled clinical trials on the use of ondansetron in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of ondansetron for radiotherapy-induced nausea and vomiting in children.
Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m². The intravenous dose must not exceed 8 mg.
Oral dosing can commence twelve hours later and may be continued for up to 5 days (Table).
The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.
BSA-based dosing for Chemotherapy – Children aged ≥6 months and adolescents:
| BSA | Day 1a,b | Days 2–6b |
|---|---|---|
| <0.6m² | 5mg/m² i.v. plus | 2mg syrup every 12 hours |
| 2mg syrup after 12 hrs | ||
| ≥0.6 m² to ≤1.2 m² | 5mg/m² i.v. plus | 4mg syrup or tablet every 12 hrs |
| 4mg syrup or tablet after 12 hrs | ||
| >1.2m² | 5mg/m² or 8mg IV plus | 8mg syrup or tablet every 12 hours |
| 8mg syrup or tablet after 12 hours |
a The intravenous dose must not exceed 8mg.
b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.
For:
Intravenous, 0.15 milligrams ondansetron per kilogram of body weight, once daily.
The dose for CINV can be calculated based on body surface area (BSA) or weight – see below.
In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 mL of saline or other compatible infusion fluid and infused over not less than 15 minutes.
Weight-based dosing results in higher total daily doses compared to BSA-based dosing.
Ondansetron injection should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid and infused intravenously over not less than 15 minutes.
There are no data from controlled clinical trials on the use of ondansetron in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of ondansetron for radiotherapy-induced nausea and vomiting in children.
Weight-based dosing results in higher total daily doses compared to BSA-based dosing.
Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The intravenous dose must not exceed 8 mg.
Two further intravenous doses may be given in 4-hourly intervals.
Oral dosing can commence twelve hours later and may be continued for up to 5 days (table). The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32mg.
Weight-based dosing for Chemotherapy – Children aged ≥6 months and adolescents:
| Weight | Day 1a,b | Days 2–6b |
|---|---|---|
| ≤10kg | Up to 3 doses of 0.15 mg/kg every 4 hours | 2mg syrup every 12 hours |
| >10kg | Up to 3 doses of 0.15 mg/kg every 4 hours | 4mg syrup or tablet every 12 hours |
a The intravenous dose must not exceed 8mg.
b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
